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Increased central sympathetic drive is a hallmark of several important clinical conditions
including essential hypertension, heart failure, chronic kidney disease, and insulin resis-
tance. Afferent signaling from the kidneys has been identiﬁed as an important contributor
to elevated central sympathetic drive and increased sympathetic outﬂow to the kidney
and other organs is crucially involved in cardiovascular control. While the resultant effects
on renal hemodynamic parameters, sodium and water retention, and renin release are
particularly relevant for both acute and long term regulation of blood pressure, increased
sympathetic outﬂow to other vascular beds may facilitate further adverse consequences of
sustained sympathetic activation such as insulin resistance, which is commonly associated
with hypertension. Recent clinical studies using catheter-based radiofrequency ablation
technology to achieve functional renal denervation in patients with resistant hypertension
have identiﬁed the renal nerves as therapeutic target and have helped to further expose the
sympathetic link between hypertension and insulin resistance. Initial data from two clinical
trials and several smaller mechanistic clinical studies indicate that this novel approach may
indeed provide a safe and effective treatment alternative for resistant hypertension and
some of its adverse consequences.
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INTRODUCTION
Although a common and growing clinical problem, there is a
lack of data on the exact prevalence of resistant hypertension,
which is commonly deﬁned as blood pressure (BP) above tar-
get levels despite the use of at least three antihypertensive agents
in adequate doses from different classes, typically including a
diuretic (Calhoun et al., 2008). Evidence from the National Health
and Nutrition Examination Survey and from large randomized
clinical trials indicate that up to 20–30% of hypertensive patients
require three or more antihypertensive agents to achieve BP tar-
gets. Failure to reach target BP levels despite therapeutic inter-
vention leaves patients at high risk for major cardiovascular
events (Calhoun et al., 2008). Developing additional approaches
to the current management of resistant hypertension consisting
of lifestyle modiﬁcation combined with poly-pharmacotherapy
remains a priority.
THE SYMPATHETIC NERVOUS SYSTEM AND BLOOD
PRESSURE REGULATION
While the pathogenesis of arterial hypertension is multi-factorial,
there is unequivocal evidence for an important role of the
sympathetic nervous system as a major contributor to the
development of hypertension and its adverse consequences with
the BP elevation being initiated and sustained by elevated sympa-
thetic nerve activity (Esler, 2000). Increased sympathetic outﬂow
to the heart resulting in increased cardiac output and neurally
mediated vasoconstriction of peripheral blood vessel are obvious
examples of neural pathways leading to elevated BP. The conse-
quences of increased sympathetic outﬂow to the kidneys, perhaps
most important in this context, are sodium and water retention,
increased renin release and alterations of renal blood ﬂow (DiBona
and Kopp, 1997), effects that again contribute substantially to BP
elevations, both acutely and in the long term (Esler, 2000; Schlaich
et al., 2009a). Furthermore, sympathetic nervous system activation
has also been implicated in alterations of glucose metabolism and
is evident in obese patients, patients with the metabolic syndrome,
and patients with diabetes (Lambert et al., 2010). Of note, hyper-
tension and alterations of glucose metabolism regularly coincide
with the sympathetic nervous system being an obvious but not
the only link between the two (Lambert et al., 2010). Accord-
ingly, targeting the sympathetic nervous system directly appears
to be a logical therapeutic approach not only for the treatment of
hypertensionbut perhaps also for additional adverse consequences
associated with sympathetic activation.
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THE SPECIFIC ROLE OF RENAL SYMPATHETIC NERVES FOR
HYPERTENSION AND CV OUTCOMES
The renal nerves are major regulators of kidney function, vol-
ume homeostasis, and BP control (DiBona and Kopp, 1997).
Assessment of regional overﬂow of norepinephrine (NE) from
the kidneys to plasma clearly demonstrated that renal norepi-
nephrine spillover rates are markedly elevated in patients with
essential hypertension (Schlaich et al., 2004) and are associated
with hypertensive target organdamage such as left ventricular (LV)
hypertrophy (Schlaich et al., 2003; Burns et al., 2007). Interestingly,
activation of cardiorenal sympathetic nerve activity is even more
pronounced in heart failure (Kaye et al., 1994), a common clinical
consequence of long term and sustained elevated BP. Renal sym-
pathetic activation has been shown to predict all-cause mortality
and heart transplantation in patients with congestive heart fail-
ure (Kaye et al., 1995). Similarly, elevated norepinephrine plasma
levels have been identiﬁed as major contributors to adverse CV
outcomes in end-stage renal disease (Zoccali et al., 2002), another
condition commonly characterized by substantially elevated sym-
pathetic nerve activity (Schlaich et al., 2009a). There is now also
substantial evidence for a speciﬁc role of sympathetic activation
in the progression of chronic kidney disease (Grassi et al., 2011),
which in turn is often a consequence of long term uncontrolled
BP (Schlaich et al., 2009a).
Increased efferent nerve activitymediates changes in renal func-
tion through innervations of all essential renal structures includ-
ing the renal vasculature, the tubules, and the juxtaglomerular
apparatus (DiBona and Kopp, 1997). Consequently, renal sympa-
thetic activation results in volume retention, sodium reabsorption,
reduction of blood ﬂow, and renin–angiotensin–aldosterone sys-
tem activation (DiBona and Kopp, 1997). The kidney however,
also has an extensive network of afferent unmyelinated ﬁbers that
transmit important sensory information to the central nervous
system (CNS; Stella and Zanchetti, 1991;DiBona and Kopp, 1997).
Afferent ﬁbers from the kidney have been shown to travel along
with the sympathetic nerves at the level of the kidney and then
enter the dorsal roots and project to neurons at both spinal and
supraspinal levels. Most of the brainstem regions involved in car-
diovascular control including the hypothalamus receive inputs
from the renal afferents which carry information to the CNS
from renal chemo- and mechano-receptors (Stella and Zanchetti,
1991; DiBona and Kopp, 1997). Direct electrical stimulation of
the renal afferent nerves in animals may produce both sympa-
thoinhibitory and sympathoexcitatory reﬂexes, which reﬂects the
diverse functional nature of various populations of renal recep-
tors (Stella and Zanchetti, 1991). While much less is known about
the normal function of the renal afferent nerves than the efferent
nerves, there is evidence that renal afferents play a role in the reﬂex
increase in sympathetic tone that occurs in hypertension (Katholi,
1983). Renal afferent nerve activity directly inﬂuences sympa-
thetic outﬂow to the kidneys and other highly innervated organs
involved in cardiovascular control such as the heart and peripheral
blood vessels, predominantly by modulating posterior hypothala-
mic activity (DiBona and Kopp, 1997;Ye et al., 1997). Interestingly,
abrogation of renal sensory afferent nerves has been demonstrated
to reduce both BP and organ speciﬁc damage caused by chronic
sympathetic overactivity in various experimentalmodels (DiBona,
2003). Targeting the renal nerves speciﬁcally therefore appears as
an obvious therapeutic strategy. Indeed, recent efforts to func-
tionally denervate the human kidneys by targeting both efferent
and afferent nerves directly via a novel catheter-based ablation
approach has sparked substantial interest in this technique as a
novel treatment strategy particularly for resistant hypertension,
but perhaps also for less severe forms of hypertension and other
conditions characterized by increased sympathetic drive (Schlaich
et al., 2010).
BENEFICIAL CONSEQUENCES OF THERAPEUTIC RENAL
DENERVATION
Renal denervation has been widely applied in experimental mod-
els of various conditions characterized by heightened sympathetic
drive and consistently demonstrated the importance of renal effer-
ent and afferent nerves and their contribution to the pathophys-
iology of hypertension, heart failure, and chronic kidney disease
(Schlaich et al., 2009b). In a large number of diverse animal mod-
els of experimental hypertension including genetic, salt sensitive,
and obesity hypertension, bilateral renal denervation prevented
the development or attenuated the magnitude of hypertension
(DiBona and Kopp, 1997).
Although more difﬁcult to assess in humans, there is convinc-
ing evidence of increased sympathetic activity in various forms of
hypertension including essential hypertension (Esler, 2000), obe-
sity related hypertension (Esler et al., 2006), renal hypertension
(Schlaich, 2011), hypertension associated with obstructive sleep
apnea (Peppard et al., 2000), and preeclampsia (Schobel et al.,
1996).
CATHETER-BASED RENAL DENERVATION: CLINICAL TRIAL
DATA AND MECHANISTIC INSIGHTS
Against this background, a recent safety and proof-of concept
study for the ﬁrst time applied a novel catheter-based technique to
selectively denervate the kidneys in patients with treatment resis-
tant hypertension (Krumet al., 2009). In this approach, renal nerve
ablation is achieved percutaneously via the lumen of the renal
artery using a catheter connected to a radiofrequency (RF) gener-
ator. After the treatment catheter (Symplicity®, Ardian, Inc., Palo
Alto, CA, USA) is introduced, four to six discrete RF ablations
are applied and separated both longitudinally and rotationally
within each renal artery (Figure 1). Catheter tip temperature
and impedance are constantly monitored during ablation and
RF energy delivery is regulated according to a predetermined
algorithm.
A total of 45 patients with a mean age of 58± 9 years and an
average BP of 177/101± 20/15 mmHg despite concurrent use of
a mean of 4.7± 1.5 antihypertensive agents were treated. Vascu-
lar safety analysis consisting of renal angiography at 14–30 days
after the procedure and MR angiographies at 6 months post-
procedure revealed no instances of renal artery aneurysm or
stenosis or other major long term adverse events. Renal function
remained unchanged, indicative of a favorable vascular and renal
safety proﬁle. The ablation procedure is typically accompanied
by diffuse visceral non-radiating abdominal pain which does not
persist beyond the RF energy application and can be managed by
intravenous narcotics and sedatives.
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FIGURE 1 | Schematic illustration of the percutaneous catheter-based
approach to functionally denervate the human kidney. Similar to a
routine angiogram access to the renal artery is obtained via a sheath in the
femoral artery. The treatment catheter is then introduced into the renal
artery and discrete RF ablation treatments lasting 2min each are applied
along the renal artery as illustrated. Up to six ablations are performed in
each artery which are separated both longitudinally and rotationally to
achieve circumferential coverage of the renal artery. Catheter tip
temperature and impedance are constantly monitored during ablation and
RF energy delivery is regulated according to a predetermined algorithm.
From a clinical perspective, the most important result of
this trial was that renal nerve ablation is associated with a sig-
niﬁcant and sustained reduction in both systolic and diastolic
ofﬁce BP up to 12 months follow up with mean (±95% CI)
decreases of −14/−10± 4/3, −21/−10± 7/4, −22/−11± 10/5,
−24/−11± 9/5, and −27/−17± 16/11 mmHg at 1, 3, 6, 9, and
12 months, respectively.
From a mechanistic point of view, it seemed important to
document the effectiveness of the procedure to reduce renal sym-
pathetic nerve activity. Radiotracer dilution methodologies were
therefore applied to assess overﬂow of norepinephrine from the
kidneys into the circulation before and after the procedure. These
analyses revealed a substantial reduction in mean norepinephrine
spillover by 47% (95%conﬁdence interval: 28–65%) 1 month after
bilateral denervation. Furthermore, it is also noteworthy that renal
denervation decreased renin secretion and increased renal blood
ﬂow (Schlaich et al., 2009c), conﬁrming successful targeting of
efferent renal nerves.
While the contribution of afferent nerves cannot be measured
directly in humans, the demonstration of a substantial and pro-
gressive reduction in central sympathetic outﬂow from baseline
through to 12 months follow up is perhaps indicative of similar
alterations in afferent ﬁber signaling that may well play an impor-
tant role in the BP effects associated with this procedure (Schlaich
et al., 2009c). Further support for a role o afferent nerves in this
scenario may be derived from experimental studies demonstrating
that rats subjected to renal surgical denervation experience func-
tional reinnervation of the renal vasculature which begins to occur
between 14 and 24 days after denervation, with complete return of
neural function by 8 weeks (Kline andMercer, 1980). It is therefore
possible that some efferent sympathetic reinnervation may occur
in patients after renal denervation, although the magnitude and
time course of this potential response is unknown. Interestingly,
in contrast to efferent nerves, the afferent nerves do not appear
to have the capacity to regrow (Arrowood et al., 1995), thereby
perhaps explaining the sustained BP lowering effect of renal den-
ervation over time via the removal of renal afferent activity and
the subsequent effects on central sympathetic outﬂow (Schlaich
et al., 2009c). Indeed, a very recent analysis summarizing the expe-
rience from longer term follow up of the initial cohort (n = 45)
and similar patients subsequently treatedwith catheter-based renal
denervation in a non-randomized and uncontrolled fashion (total
n = 153) demonstrated the sustained efﬁcacy of renal nerve abla-
tion with post-procedure ofﬁce BP being reduced by 32/14 mmHg
at 24 months follow up (Krum et al., 2011; Figure 2).
Additional factors that may translate into better outcomes after
renal denervation include improvements in cardiac baroreﬂex
sensitivity (from 7.8 to 11.7 ms/mmHg) and a reduction in LV
mass from 184 to 169 g (78.8–73.1 g/m2) at 12 months follow up
compared to baseline (Schlaich et al., 2009c).
Very recently, results from the ﬁrst randomized controlled
clinical trial including a total of 106 patients were published (Esler
et al., 2010). Inclusion criteria were similar to those of the ini-
tial safety and proof-of concept trial with patients required to
have a baseline systolic ofﬁce BP≥ 160 mmHg (≥150 mmHg for
patients with type 2 diabetes) despite compliance with ≥3 antihy-
pertensive medications. Patients were then randomized to either
undergo renal nerve ablation treatment (n = 52) or to continue
with conventional drug treatment as part of the control group
(n = 54).
Both groups had similar baseline characteristics and antihyper-
tensive regimen with the exception of estimated glomerular ﬁltra-
tion rate (eGFR) which was lower in the active treatment group
(77 vs. 86 ml/min, p = 0.013). Peri-procedural events requiring
treatment were rare. In keeping with the results from the ﬁrst trial,
a signiﬁcant difference in the primary endpoint of seated ofﬁce
BP of 33/11 mmHg (p< 0.001 for both systolic and diastolic BP)
was noted between the renal denervation group and the control
group. Home BP recordings conﬁrmed the observed ofﬁce BP
changes with a reduction in home BP by 20/12± 17/11 mmHg in
the renal denervation group and a rise of 2/0 ± 13/7 mmHg in the
control group (p< 0.001; Figure 3). BP control deﬁned as systolic
BP< 140 mmHg was achieved in 39% of patients in the denerva-
tion groupand in3%of patients in the control group.However, it is
also important tonote that there is substantial variability in regards
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FIGURE 2 | Mean systolic and diastolic blood pressure changes from baseline after renal denervation with up to 2 years of follow up.
to the BP effects and that the procedure fails to reduce BP in∼10%
of treated patients. Whether this may be related to age of patients,
duration of hypertension, established target organ damage, the
number of ablation treatments or other factors is currently unclear.
RENAL DENERVATION AND GLUCOSE METABOLISM
While the available evidence indicates that catheter-based renal
denervation has a favorable safety proﬁle and results in substantial
and sustained BP reduction in patients with drug resistant hyper-
tension, the beneﬁt of renal denervation may not be restricted
to BP lowering alone. Hypertension is frequently associated with
metabolic alterations such as overweight and obesity, impaired
fasting glucose, impaired glucose tolerance, and insulin resis-
tance and sympathetic activation has clearly been identiﬁed as
an important contributor to this detrimental clinical scenario
(Lambert et al., 2010). Sympathoinhibition would therefore be
expected to improve glycemic control (Straznicky et al., 2011a).
Indeed, in a group of patients who either had renal denervation
(n = 37) or served as controls (n = 13), detailed assessment of
glucose metabolism was performed by assessing fasting glucose,
insulin, C-peptide, HbA1c, calculated insulin sensitivity (HOMA-
IR), and glucose levels during oral glucose tolerance test (OGTT)
at baseline and at 1 and 3 months follow up (Mahfoud et al.,
2011). In addition to the BP fall observed in the treatment group
(−32/−12 mmHg) after 3 months, fasting glucose [from118 ± 3.4
to 108± 3.8 mg/dl (p = 0.039)], insulin levels [from 20.8± 3.0 to
9.3± 2.5μIU/ml (p = 0.006)], C-peptide levels [from 5.3 ± 0.6 to
3.0± 0.9 ng/ml (p = 0.002)], and theHOMA-IR [from6.0± 0.9 to
2.4± 0.8 (p = 0.001)] also improved signiﬁcantly after 3 months
(Figure 4). Additionally, mean 2-h glucose levels during OGTT
were reduced signiﬁcantly by 27 mg/dl (p = 0.012) while there
were no signiﬁcant changes in BP or any of the metabolic markers
in the control group.
Further support for such a beneﬁcial role comes from investi-
gations of yet another group of patients commonly characterized
by overweight or obesity, sympathetic nervous system activa-
tion, insulin resistance, and BP elevation, namely women with
polycystic ovary syndrome. Using the gold standard method-
ology of euglycemic hyperinsulinemic clamp, it was demon-
strated that insulin sensitivity improved by 17.5% in the absence
of any weight changes at 3 months after renal denervation. Of
note, glomerular hyperﬁltration and urinary albumin excretion
were also reduced indicating that the beneﬁts of renal den-
ervation may also extend to renal structure and function, as
suggested previously (Schlaich et al., 2009a,b; Straznicky et al.,
2011b).
While the effects of renal denervation on glucose metabo-
lism described above are primarily of descriptive nature, there
is ample evidence highlighting potential mechanisms through
which inhibition of sympathetic activation could improve glucose
metabolism.
In the human forearm, increased noradrenaline release results
in a substantial reduction in forearm blood ﬂow (Jamerson et al.,
1993). This is associated with a markedly reduced uptake of
glucose, demonstrating the adverse effect of sympathetic acti-
vation on the ability of the cell to transport glucose across its
membrane (Jamerson et al., 1993). Experimental and clinical
data indicate that the rate of diffusion of a substance decreases
with the square of the distance to its target (Rasio, 1975),
that there is a direct relationship between the sympathetic
nerve ﬁring rate to skeletal muscle tissue and insulin resis-
tance (Grassi et al., 2004) and that insulin resistance is inversely
related to the number of open capillaries (Egan, 1991). Fur-
thermore, this situation may be enhanced if insulin resistance
is already established, a state in which the ability of insulin to
increase muscle perfusion has been demonstrated to be reduced
by ∼30% (Laakso et al., 1990). In view of these data it is
perhaps not surprising that a procedure that reduces sympa-
thetic nerve activity can also result in improvements of glucose
metabolism.
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FIGURE 3 | Change in systolic and diastolic office blood pressure in the renal denervation group and the control group, respectively.
FIGURE 4 | Change in fasting glucose, insulin levels, C-peptide levels, and the HOMA-IR in the renal denervation group and the control group,
respectively.
CONCLUSION
In summary, ﬁndings from the initial safety and proof-of-concept
study and one randomized controlled clinical trial indicate that
renal nerve ablation achieved via a novel catheter-based approach
using RF energy is safe and has the potential to improve BP
control and alleviate the sequelae of elevated BP in patients
with resistant hypertension. These beneﬁcial effects appear to
be mediated via interference with both efferent and afferent
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nerves and are likely to extend to improvements in metabolic
control.
Whether this novel approach may also be useful in less severe
forms of hypertension or in other conditions characterized by
heightened renal sympathetic nerve activity such as chronic and
end-stage renal disease needs to be determined in future studies.
On the basis of the known pathophysiology, patients with either
chronic or end-stage renal disease and those with heart failure also
appear to be suitable candidates for such an approach, given the
evidence from both experimental and human studies to indicate
that efferent and afferent signaling are crucially involved in the
sympathetic activation almost invariably present in these patients.
Other patients who may beneﬁt from such an approach are those
intolerant to pharmacological treatment. Several clinical trials are
currently being conducted and planned to further substantiate the
BP lowering efﬁcacy of this novel renal denervation procedure and
to identify patient cohorts that are likely to beneﬁt from such an
approach.
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